• A Hjalmarson, D Elmfeldt, J Herlitz, S Holmberg, I Málek, G Nyberg, L Rydén, K Swedberg, A Vedin, F Waagstein, A Waldenström, J Waldenström, H Wedel, L Wilhelmsen, and C Wilhelmsson.
• Lancet. 1981 Oct 17; 2 (8251): 823-7.

AbstractThe effect of metoprolol on mortality was compared with that of placebo in a double blind randomised trial in patients with definite or suspected acute myocardial infarction. Treatment with metoprolol or placebo started as soon as possible after the patient's arrival in hospital and was continued for 90 days. Metoprolol was given as a 15 mg intravenous dose followed by oral administration of 100 mg twice daily. 1395 patients (697 on placebo and 698 on metoprolol) were included in the trial. Definite acute myocardial infarction developed in 809 and probable infarction in 162. Patients were allocated to various risk groups and within each group patients were randomly assigned to treatment with metoprolol or placebo. There were 62 deaths in the placebo group (8.9%) and 40 deaths in the metoprolol group (5.7%), a reduction of 36% (p less than 0.03). Mortality rates are given according to the treatment group to which the patients were initially randomly allocated.

19 keywords...

hide…